Efficacy of Agomelatine 25mg/Day (With Possible Increase to 50mg/Day After 8 Weeks of Treatment) Given Orally During 16 Weeks in Patients With Obsessive-Compulsive Disorder. A Randomised, Double-blind, Placebo-controlled, Parallel Groups, International Study.
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2014
At a glance
- Drugs Agomelatine (Primary)
- Indications Obsessive-compulsive disorders
- Focus Therapeutic Use
- Sponsors Servier
- 09 Apr 2014 Last checked against ClinicalTrials.gov record.
- 12 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 May 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.